S. Beattie

发表

Natural History of Cardiovascular Disease in Patients With Diabetes

M. Hanefeld, B. Campaigne, I. Kowalska, 2008, Diabetes Care.

Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

B. Campaigne, Z. Milicevic, S. Beattie, 2003, Diabetes research and clinical practice.

Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.

J. Bue-Valleskey, S. Del Prato, A. Ceriello, 2007, Journal of diabetes and its complications.

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

D. M. van der Heijde, C. Zerbini, S. de Bono, 2017, Arthritis & rheumatology.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

D. M. van der Heijde, M. Weinblatt, E. Keystone, 2017, The New England journal of medicine.

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

M. Genovese, E. Keystone, P. Taylor, 2018, The Journal of Rheumatology.

Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND

Yoshiya Tanaka, P. Durez, S. Beattie, 2021, The Journal of Rheumatology.

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

P. Emery, Yoshiya Tanaka, J. Smolen, 2020, Arthritis Research & Therapy.

This is a repository copy of Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

C. Peterfy, M. Genovese, P. Emery, 2020 .

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

C. Peterfy, M. Genovese, P. Emery, 2019, The Journal of Rheumatology.

LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study

M. Dougados, P. Emery, D. Heijde, 2015 .

Longterm Extension Study in Patients with Rheumatoid Arthritis Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label ,

M. Genovese, E. Keystone, P. Taylor, 2017 .

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

P. Emery, Yoshiya Tanaka, J. Smolen, 2020, Arthritis Research & Therapy.

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

M. Dougados, D. M. van der Heijde, P. Emery, 2016, Annals of the rheumatic diseases.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

J. Kremer, M. Genovese, S. de Bono, 2016, The New England journal of medicine.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

M. Genovese, E. Keystone, P. Taylor, 2014, Annals of the rheumatic diseases.

Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design.

J. Wyatt, D. Robbins, I. Raz, 2005, Journal of diabetes and its complications.

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

M. Genovese, E. Keystone, P. Taylor, 2012 .

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

C. Peterfy, M. Genovese, P. Emery, 2012 .

FRI0124 Temporary interruptions of study drug during the baricitinib phase 3 rheumatoid arthritis program

P. Emery, Yoshiya Tanaka, J. Smolen, 2017 .

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis

J. Kremer, M. Genovese, E. Keystone, 2017, Arthritis & rheumatology.

OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

J. Kremer, M. Genovese, A. Koch, 2015 .

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

H. L. Wright, R. Moots, T. Spector, 2013 .

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS

M. Genovese, E. Keystone, P. Taylor, 2013 .

A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1

Mark C. Genovese, Scott D. Beattie, M. Genovese, 2013 .

supplement to: Baricitinib versus placebo or adalimumab in rheumatoid arthritis.

D. M. van der Heijde, M. Weinblatt, E. Keystone, 2017 .